NRIX

Nurix Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1549595Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$84.0M

Net Income FY2025

$(264.0M)

EPS (Basic, as reported)

$-3.05

Net Margin FY2025

-314.9%

ROE FY2025

-49.1%

Total Equity

$539.0M

Shares Out

104M

Business description

Nurix Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 31 → 84 +18.1% CAGR

Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue31183039775584

Research & development(45)(66)(116)(184)(189)(222)(317)

General & administrative(8)(16)(31)(38)(43)(46)(53)

Total operating expenses(53)(83)(148)(222)(232)(268)(370)

Operating income(22)(65)(118)(184)(155)(213)(286)

Pre-tax income(21)(64)(117)(180)(144)(193)(264)

Income tax expense0(21)0000(1)

Net income(22)(43)(117)(180)(144)(194)(264)

EPS — basic——($2.73)($3.71)($2.65)($2.88)($3.05)

EPS — diluted——($2.73)($3.71)($2.65)($2.88)($3.05)

Shares outstanding — basic (M)——4349546787

Shares outstanding — diluted (M)——4349546787

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.